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Rat Monoclonal Antibodies Specific for LST1 Proteins
Christian Schiller,1,2 Maximilian J.E. Nitschke´,1 Alexander Seidl,1
Elisabeth Kremmer,2 and Elisabeth H. Weiss1
The LST1 gene is located in the human MHC class III region and encodes transmembrane and soluble isoforms
that have been suggested to play a role in the regulation of the immune response and are associated with
inflammatory diseases such as rheumatoid arthritis. Here we describe the generation and characterization of the
first monoclonal antibodies against LST1. Two hybridoma lines secreting monoclonal antibodies designated 7E2
and 8D12 were established. The 7E2 antibody detects recombinant and endogenous LST1 by Western blot
analysis while 8D12 reacts with recombinant and endogenous LST1 in immunoprecipitation and flow cytometry
procedures. The newly established antibodies were used to survey LST1 protein expression in human cell lines,
which was found to be tightly regulated, allowing the expression of transmembrane isoforms but suppressing
soluble isoforms.
Introduction
T he MHC class III region encodes numerous genesinvolved in the inflammatory response and harbors the
LST1 (leukocyte specific transcript 1) gene.(1) LST1 transcripts
are strongly present in immune cells, especially B cells, T cells,
monocytes, and dendritic cells,(2) and their expression has been
shown to be drastically upregulated by inflammatory stimuli.(3,4)
LST1 transcripts undergo extensive alternative splicing, resulting
in 17 splice variants that encode 12 transmembrane or soluble
isoforms. Five distinct transcriptional start sites have been
identified in the LST1 gene.(5) The alternative exon 1 sequences
result in transcripts differing in the 50-untranslated region (50-
UTR). Thus, translational control of LST1 mRNAs through the
50-UTR may represent an additional mechanism to regulate
LST1 expression in immune cells. All LST1 splice variants
contain the exon 2 sequence, which harbors the common
translation initiation site, but varywith regard to the presence of
exon 3 and exon 4, respectively, and in the length of the last exon
5. Transcripts lacking the transmembrane-helix-encoding exon
3 code for short soluble polypeptides, whereas transcripts
lacking exon 4 undergo a translational frameshift, which results
in a premature stop codon and an alternative carboxyterminal
amino acid sequence. Finally, two additional splice sites are
present in the exon 5 sequence (exon 50=exon 5@), further adding
to isoform diversity. Here we name the different LST1 isoforms
based on the protein coding exons present in the respec-
tive transcript but also specify the letter designations(4,6) (Fig. 1).
It has been proposed that LST1 isoforms play an im-
portant role in regulating the immune response(6) and
enabling cell-cell communication,(7) but the exact mecha-
nisms involved are yet to be elucidated. Recent work has
also shown that high LST1 expression levels are associated
with several inflammatory diseases including rheumatoid
arthritis(4) and the inflammatory response believed to cause
neural tube defect.(8) These associations, however, have
been established based on mRNA expression data and have
not been validated at the protein level. To allow insights
into the structure and function of LST1 isoforms and to dis-
cern their potential role in autoimmune diseases, we gen-
erated and characterized rat monoclonal antibodies specific
for LST1.
Experimental Procedures
Isolation and detection of LST1 transcripts
Total RNA was isolated from human U-937 cells using the
Trizol reagent (Invitrogen, Paisley, United Kingdom). Tran-
scriptswere amplifiedusing theOneStepRT-PCRKit (Qiagen,
Hilden, Germany) following the manufacturer’s instructions
and using primers flanking the longest open reading frame
of LST1 (5-Lst2s: 50-GCAAGGACTAGAGTTCCTGAC-30;
3-Lst1A: 50-CGGATCCTTATCAGGTGGGTTTGTTCTC-30).
Amplification products were separated on 2% agarose gels,
together with a molecular weight marker (1Kb Plus DNA
Ladder, Invitrogen).
Cloning of a HIS-LST1 expression construct
The HIS-LST1.3D450 construct was cloned by amplifying
the mutated LST1.3D450 cDNA (by exon usage: 3D [lacking
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the sequence encoding the transmembrane helix], 4 and 50)
using the following primers: 5-Lst3-Bgl: 50-CAGATCTAT
CCGCCTGCCTGTGTTG-30 and 3-Lst1A as described above.
The LST1.3D450 PCR product was subcloned into the pCRII
vector using the TOPO TA cloning kit (both from Invitrogen)
and subsequently cloned into the pET-45b (þ) vector (Nova-
gen, Gibbstown, NJ).
Generation of monoclonal rat anti-LST1 antibodies
Recombinant HIS-LST1 was generated by transforming the
HIS-LST1.3D450 vector into BL21 Codon Plus (DE3)-RIPL
bacteria (Stratagene, La Jolla, CA) and induction of protein
expression by treatment with 1mM IPTG (Carl Roth, Karls-
ruhe, Germany) for 3 h while shaking at 378C. Bacterial ex-
tracts were prepared with lysis buffer (50mM sodium
phosphate buffer [pH 7.4], 300mM NaCl, 0.2mg=mL lyso-
zyme, and complete protease inhibitor cocktail; Roche
Diagnostics, Mannheim, Germany) for 30min at 48C. Subse-
quently lysates were adjusted to 2M urea and sonicated using
a Sonifier 250 (Branson, Pusan, Korea). To remove unsoluble
debris, lysates were spun at 40,000 g at 48C for 45min fol-
lowed by filtration of supernatants through a 0.2 mm pore
sterile filter. Purification of HIS-LST1 from bacterial extracts
was achieved by affinity chromatography using ProPur
IMAC Midi columns (Nunc, Langenselbold, Germany) fol-
lowing the manufacturer’s recommendations. Approximately
50 mg of the purified HIS-LST1-fusion protein were injected
both intraperitoneally (i.p.) and subcutaneously (s.c.) into
Lou=C rats using CPG2006 (TIB MOLBIOL, Berlin, Germany)
as adjuvant. After an 8-week interval, a final i.p. and s.c. boost
was given 3 days before fusion. Fusion of the rat spleen cells
was performed with the myeloma cell line P3X63-Ag8.653.
Hybridoma supernatants were tested in a solid-phase im-
munoassay. HIS-LST1-fusion protein was coated overnight at
a concentration of 3mg=mL. After blocking with non-fat milk,
hybridoma supernatants were added. Bound rat monoclonal
antibodies (MAbs) were detected with a cocktail of biotiny-
lated mouse MAbs against the rat IgG heavy chains (a-IgG1,
a-IgG2a, a-IgG2b from ATCC, Manassas, VA; a-IgG2c, As-
cenion, Munich, Germany), thus avoiding IgM MAbs. The
biotinylated MAbs were visualized with peroxidase-labeled
Avidin (Alexis, Gruenberg, Germany) and o-phenylenedia-
mine as chromogen in the peroxidase reaction. Clones LST1
7E2 of rat IgG2b subclass and LST1 8D12 of IgG2a subclass
were stably subcloned and used for further analysis.
Cell culture and transfection procedures
In this study the following human cell lines were used: the
pancreatic adenocarcinoma cell line Capan-1 (ATCCHTB-79),
the embryonic kidney cell line HEK 293T (ATCC CRL-11268),
the cervix adenocarcinoma cell line HeLa 229 (ATCC CCL-
2.1), the colorectal adenocarcinoma cell line HT-29 (ATCC
HTB-38), the acute T cell leukemia line Jurkat (ATCCTIB-152),
the chronic myelogenous leukemia cell line K-562 (ATCC
CCL-243), the malignant melanoma cell line SK-MEL-28
(ATCC HTB-72), the glioblastoma cell line U-251 MG (ATCC
HTB-17), and the histiocytic lymphoma cell line U-937 (ATCC
CRL-1593.2). Cell lines were cultivated as recommended by
ATCC. HEK 293T cells were transiently transfected as de-
scribed previously.(9) U-937 stable transfectants were estab-
lished by electroporation using an Electro Cell Manipulator
600 (BTX, Holliston, MA), with the following settings: 175V,
1300 mF, 129O. Negative selectionwas achieved by cultivating
transfectants in growth medium containing 2.5mg=mL G418
(PAA, Pasching, Austria) 48 h after electroporation. Clones
were screened by FACS and Western blot analysis.
Flow cytometry
For flow cytometry, cells were washed and resuspended
in PBS containing 5% FCS. Staining was performed with
the LST1 8D12 antibody (undiluted hybridoma supernatant)
and a PE-conjugated goat anti-rat antibody (1:50, Dianova,
Hamburg, Germany). After staining, cells were fixated in 1%
PFA=PBS. For intracellular staining, cells were fixated in 4%
PFA=PBS prior to staining and antibody dilutions were sup-
plemented with 0.1% Saponin. For each staining, 10,000 cells
were analyzed using a FACSCalibur cytometer and Cell
Quest software (both from Becton Dickinson, Franklin Lakes,
NJ).
Immunoprecipitation and Western blot analysis
Immunoprecipitation was performed with either 107 HEK
293T or 3107 U-937 cells. Cell lysates were prepared with
lysis buffer (50mM Tris-HCl [pH 8.0], 150mM NaCl, 1%
Triton X-100, and complete protease inhibitor cocktail) for
30min at 48C followed by centrifugation at 13000 g and 48C
for 30min to clear the lysate. Lysates were rolled at 48C
overnight with the LST1 8D12 antibody (100mL hybridoma
supernatant). The antibody-antigen complexes were subse-
quently coupled to 20mL Protein G Sepharose beads (50% v=v,
Amersham, Buckinghamshire, UK) by rolling for 1 h at 48C.
Beads were washed with lysis buffer and stored in SDS
sample buffer (Roti-Load 1, Roth) at 208C. Western blot
analysis was performed by boiling either the beads or cell
lysates from 106 cells in SDS sample buffer followed by sep-
aration on a 15% polyacrylamide gel; additionally 1 mL of the
prestained molecular weight marker Broad Range (Cell Sig-
naling, Danvers, MA)was loaded onto each gel. Proteinswere
blotted overnight onto an Immobilion-FL PVDF membrane
(Millipore, Schwalbach, Germany). To detect recombinant
LST1, either the LST1 7E2 antibody (1:100, hybridoma su-
pernatant) or the FLAG M2 antibody (1:1000, Sigma-Aldrich,
Taufkirchen, Germany) was used. Endogenous LST1 was
detected with the 7E2 antibody (1:10, hybridoma superna-
tant). Fluorescence detection was conducted with IRDye800-
coupled goat anti-mouse and goat anti-rat antibodies
(1:10,000, Rockland, Gilbertsville, PA). For blot imaging, the
Odyssey infrared imaging system (Li-cor, Lincoln, NE) was
used.
Results
Detection of recombinant and endogenous
LST1 via Western blot analysis
To ascertain whether the rat monoclonal 7E2 antibody
detects different LST1 isoforms, recognition of several N- and
C-terminally FLAG-tagged LST1 isoforms produced by tran-
siently transfected HEK 293T cells was assayed via Western
blot analysis. The LST1 7E2 antibody clearly detected the
transmembrane FLAG-LST1.23450 isoform (by exon usage of
the coding transcript 2, 3, 4, and 50) and itsmultimers but none
of its C-terminally truncated degradation products (Fig. 1A,
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upper left panel, lane 1). Additionally the soluble FLAG-
LST1.245 isoform was clearly bound by the antibody
(Fig. 1A, upper left panel, lane 5). Carboxyterminally tagged
LST1.23450-FLAG was not recognized, but a slightly trun-
cated form lacking the C-terminal FLAG-tag (Fig. 1A, upper
left panel, lane 2) was detected, indicating that the presence of
the tag at the C-terminus interferes with antibody binding.
Moreover, 7E2 did not react with the frame-shifted LST1.2350
isoform, regardless of the location of the FLAG tag (Fig. 1A,
upper left panel, lanes 3 and 4). The epitope recognized by the
7E2 antibody was determined with a mutant construct
(FLAG-LST1.2345D lacking the last 13 C-terminal amino acids
FIG. 1. Specificity of the rat monoclonal LST1 antibody 7E2. (A) Detection of recombinant LST1 by Western blot analysis.
HEK 293T cells were transiently transfected with constructs encoding either N- or C-terminally FLAG-tagged LST1
(LST1.2345¼LST1=P; LST1.23450 ¼LST1=ABG; LST1.2350 ¼LST1=K; LST1.245¼LST1=J). Lysates from transfectants were
probed by Western blotting using the rat monoclonal LST1 antibody 7E2 (upper panels). Subsequently blots were stripped
and reprobed with the FLAG specific antibody (lower panels). (B) Detection of endogenous LST1 by Western blot analysis.
Lysates from HeLa and U-937 cells were probed by Western blotting using either the LST1 7E2 antibody (upper panel) or a
HIS-LST1–pre-adsorbed LST1 7E2 antibody (lower panel). The position of the detected isoform LST1.2345 in its monomeric
(mLST1) and dimeric (dLST1) form is indicated. (C) Binding epitope of the LST1 7E2 antibody. Amino acid sequence
comparison of the recombinant LST1 isoforms probed in A. The amino acids encoded by exon 4 in the respective transcripts
are underscored. The FLAG tag and the vector-encoded carboxyterminus of the truncated LST1.2345D polypeptide are
italicized. The epitope recognized by the 7E2 antibody is highlighted in grey.
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of full-length transmembrane LST1.2345. The LST1 7E2 anti-
body was unable to detect the truncated polypeptide (Fig. 1A,
upper right panel). This allowed us to identify the 7E2 epitope
in the C-terminal region of full-length LST1 (highlighted in
Fig. 1C) and to conclude that the 7E2 antibody can detect all
LST1 isoforms encoded by exon 4 containing splice variants.
Endogenous LST1 was detected by the 7E2 antibody in
lysates from U-937 and HeLa cells. Only the full-length
transmembrane LST1.2345 isoform (calculated molecular
weight of 11.7 kDa) was observed as a monomer and as a
possible homodimer (Fig. 1B). The reduced mobility of
LST1 polypeptides in polyacrylamide gel electrophoresis has
beenpreviously observed.(7) Antibody specificitywas ensured
by pre-adsorbing the 7E2 antibody with recombinant HIS-
LST1 prior to immune detection, which failed to detect en-
dogenous LST1 (Fig. 1B).
Detection of native LST1 via immunoprecipitation
and flow cytometry procedures
The ability of the rat monoclonal LST1 8D12 antibody,
which poorly recognized LST1 isoforms in Western blot an-
alyses, to bind native LST1 was tested by immunoprecipitat-
ing recombinant FLAG-LST1.2345 and FLAG-LST1.245 from
lysates of transiently transfected HEK 293T cells. The 8D12
antibody precipitated both transmembrane FLAG-LST1.23450
and soluble FLAG-LST1.245 (Fig. 2A, left panel). The 8D12 an-
tibody also precipitated endogenous LST1.2345 from lysates
of U-937 cells (Fig. 2A, right panel). Furthermore, using flow
cytometry, the 8D12 antibody detected endogenous LST1 in
U-937 cells by intracellular staining. To assure binding spec-
ificity, a stable U-937 transfectant producing LST1.23450-
FLAG was analyzed and revealed higher LST1 expression
than that of untransfected U-937 cells (Fig. 2B).
LST1 expression in human cell lines
underlies tight regulation
In previous studies we detected LST1mRNA expression in
a number of tissues and cells. Transcripts predominated in
immune cells and the number of different splice variants
found in these cells was higher than in cells from non-lym-
phoid tissue.(2) Using the LST1 7E2 antibody, we found LST1
protein expression in cell lines of hematopoetic origin (U-937,
K-562, Jurkat) but also in cell lines originating from diverse
tissues (Fig. 3A). Only a polypeptide corresponding to the
full-length isoformLST1.2345was detected as amonomer and
as a possible homodimer. Even in U-937 cells, which express
different LST1 transcripts, including the splice variant en-
coding the soluble isoform LST1.2450 (Fig. 3B), only the full-
length polypeptidewas detected. In contrast tomRNAresults,
LST1 protein levels were not higher in cells of immune origin
nor were additional isoforms detected in these cells (Fig. 3A).
Variability between the assayed cell lines was solely based on
the distribution of LST1.2345 between its monomeric and
dimeric form. Repeated efforts to detect the main soluble
isoforms LST1.245=50 in a number of cell lines were unsuc-
cessful (data not shown) and lead us to speculate that ex-
pression of LST1 is tightly regulated at the translational or
post-translational level, resulting in the selective expression of
FIG. 2. Reactivity of the rat monoclonal LST1 antibody 8D12. (A) Immunoprecipitation of recombinant and endogenous
LST1. HEK 293T cells were transiently transfected with constructs encoding either transmembrane FLAG-LST1.23450 or
soluble FLAG-LST1.245. Recombinant FLAG-LST1 was precipitated using the LST1 8D12 antibody. Precipitates were probed
via Western blot using the FLAG antibody (left panel). Endogenous LST1 was precipitated from U-937 lysates with either the
LST1 8D12 or a rat control antibody of the same isotype. Precipitates were probed by Western blot using the LST1 7E2
antibody (right panel). The positions of recombinant and endogenous LST1 isoforms and of IgG light (lc) and heavy (hc)
chains are marked. (B) FACS analysis of LST1 expression. U-937 cells (continuous line) and a stable U-937 LST1.23450-FLAG
transfectant (dotted line) were stained directly (extracellular) or after permeabilization (intracellular) with the LST1 8D12
antibody. A rat antibody of the same isotype was used as a non-specific control (grey curve).
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transmembrane LST1.2345 and in the suppression of soluble
LST1.245=50.
Discussion
In the present study we generated the first monoclonal
antibodies against LST1. Characterization of the LST1 7E2
antibody revealed that it detects both recombinant and en-
dogenous LST1 via Western blot analysis, but fails to bind
non-denatured LST1 polypeptides (data not shown). The
binding epitope was localized to the 13 carboxyterminal
amino acids present in the six LST1 isoforms encoded by exon
4 containing splice variants. The LST1 8D12 antibody reacted
with native recombinant and endogenous LST1 in both im-
munoprecipitation and flow cytometry procedures. Immuno-
precipitation of recombinant LST1 isoforms revealed that the
8D12 antibody is able to bind at least four LST1 isoforms.
Using the LST1 7E2 antibody, we detected LST1 in a number
of human cell lines. Expression was not limited to immune
cells but was found in all examined cell lines at comparable
levels. With both antibodies only the full-length transmem-
brane isoform LST1.2345 was detected, although all isoforms
with internal in-frame deletions are recognized by both anti-
bodies (see Figs. 1A and 2A). The failure to detect endogenous
soluble LST1.245=50 is not due to rapid export, as we did not
detect any LST1 polypeptides in concentrated cell culture
supernatants, even of high-expressing HEK 293T transfec-
tants (data not shown). Only a polypeptide corresponding to
the longest LST1 isoform, LST1.2345, was also found by Ra-
ghunatan and colleagues probing human dendritic cells with
a polyclonal LST1-peptide specific serum.(6) These results
stand in contrast to previous findings at the mRNA level,
which stated higher amounts and an increase in splice var-
iants in immune cells when compared to cells from non-
lymphoid tissues.(2) In all cell lines tested, only the full-length
LST1 isoform was detected, although based on mRNA results
soluble isoforms (see LST1.2450 in Fig. 3B) should predomi-
nate.(4) Moreover, HEK 293T cells transiently transfected with
the FLAG-LST1.245 vector regularly displayed a substantially
weaker expression than the transmembrane isoforms (Fig.
1A). Thus, shorter LST1 polypeptides are either rapidly de-
graded or are synthesized at a lower level. It is possible that
shorter LST1molecules need to be stabilized by a partner. The
discrepancy between LST1 transcript and protein expression
leads us to propose that LST1 expression is tightly regulated at
the translational or post-translational level. Previous studies
found that in rheumatoid arthritis–affected blood and syno-
vium cells LST1 splice variants encoding soluble isoforms
were drastically upregulated.(4) We propose that in inflam-
mation the suppression of soluble isoforms is defeated by
transcriptional activation. The monoclonal LST1 antibodies
generated and characterized in this study should provide
powerful tools for future research into the role of LST1 in
inflammatory diseases.
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